Sales Support:
sales@worldwidemarketreports.com
U.S. :+1 415 871 0703
U.K. :+44-203-289-4040
AUS. : +61-2-4786-0457
INDIA :+91-848-285-0837
Menu Icon Close Icon
We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.

Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)

Executive Summary

According to Azoth Analytics research report, the Alzheimer's disease Therapeutics- Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials.

The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease.

Alzheimer's prevalence is rising rapidly and despite decades of research, the disease remains incurable. The majority of therapeutics target symptom reduction and slowing the progression of the disease. The Food and Drug Administration (FDA) approved aducanumab (Aduhelm) for the treatment of certain cases of Alzheimer's disease in June 2021 and this is the first drug approved for Alzheimer's disease in decades.
Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario.

Scope of the Report

• The report analyses the Alzheimer's Disease Therapeutics in the Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others).
• The report analyses Alzheimer's disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other).
• The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical).
• The Alzheimer's Disease Therapeutics- Pipeline Analysis has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
• The key insights of the report have been presented through the leading company shares.
• Also, the major trends, drivers and challenges as well as unmet needs of the industry has been analysed in the report.
• The companies analysed in the report include Eli-Lily & Co, Elsal Co., Ltd., BioVie, Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S, Novartis, Cognition Therapeutics, Merck Sharp & Dohme LLC, Biogen.

Key Target Audience

• Alzheimer's Disease Therapeutics Companies
• End Users (Hospitals and clinics)
• Research and Development (R&D) Organizations
• Government Bodies & Regulating Authorities
• Investment Banks and Equity Firms

1. Introduction
1.1 Alzheimer's Disease Therapeutics Overview
1.2 Scope of Research

2. Executive Summary
2.1 Market Dashboard
2.2 Regional Insights
2.3 Market Ecosystem Factors

3. Research Methodology
3.1 Data Collection Process
3.2 Market Size Calculation-Top-to-Bottom

4. Macro Economic Indicator Outlook
4.1 Global, Region-wise GDP Growth
4.2 Global Medical Spending
4.3 Current Healthcare Expenditure
4.4 Pharmaceutical Spending/capita

5. Competitive Positioning
5.1 Companies - Product Positioning
5.2 Competitive positioning
5.2.1 Eli-Lily & Co
5.2.2 Elsal Co., Ltd.
5.2.3 BioVie
5.2.4 Johnson & Johnson
5.2.5 Otsuka Pharmaceutical Co., Ltd.
5.2.6 H. Lundbeck A/S
5.2.7 Novartis
5.2.8 Cognition Therapeutics
5.2.9 Merck Sharp & Dohme LLC
5.2.10 Biogen

6. Alzheimer's disease background
6.1 AD Fact Sheet
6.2 Epidemiology
6.3 Causes and Risk Factors
6.4 Diagnosis and Assessment
6.5 Unmet Needs

7. Therapeutics in Pipeline
7.1 Pipeline Scenario
7.2 Alzheimer's Therapeutics Comparative Review

8. Pipeline Analysis

9. Phase I therapeutics Overview
9.1 LY3372993
9.1.1 Drug Description
9.1.2 Outcomes
9.2 Lu AF87908
9.2.2 Drug Description
9.2.3 Outcomes
9.3 anle138b
9.3.1 Drug Description
9.3.2 Outcomes
9.3.3 Collaborators
9.4 ASN51
9.4.1 Drug Description
9.4.2 Outcomes
9.4.3 Collaborators
9.5 CMS121
9.5.1 Drug Description
9.5.2 Outcomes
9.5.3 Collaborators
9.6 IBC-Ab002
9.6.1 Drug Description
9.6.2 Outcomes
9.6.3 Collaborators
9.7 LX1001
9.7.1 Drug Description
9.7.2 Outcomes
9.8 MK-2214
9.8.1 Drug Description
9.8.2 Outcomes
9.9 MK-8189
9.9.1 Drug Description
9.9.2 Outcomes
9.10 ACU193
9.10.1 Drug Description
9.10.2 Outcomes
9.10.3 Collaborators
9.11 NIO752
9.11.1 Drug Description
9.11.2 Outcomes
9.12 ALN-APP
9.12.1 Drug Description
9.12.2 Outcomes
9.13 TB006
9.13.1 Drug Description
9.13.2 Outcomes
9.14 SNK01
9.14.1 Drug Description
9.14.2 Outcomes
9.15 Pepinemab
9.15.1 Drug Description
9.15.2 Outcomes
9.15.3 Collaborators
9.16 GB-5001
9.16.1 Drug Description
9.16.2 Outcomes
9.17 AC-1202
9.17.1 Drug Description
9.17.2 Outcomes
9.18 SHR-1707
9.18.1 Drug Description
9.18.2 Outcomes
9.19 BEY2153
9.19.1 Drug Description
9.19.2 Outcomes
9.20 JNJ-40346527
9.20.1 Drug Description
9.20.2 Outcomes
9.20.3 Collaborators
9.21 APNmAb005
9.21.1 Drug Description
9.21.22 Outcomes
9.22 NPT 2042
9.22.1 Drug Description
9.22.2 Outcomes
9.23 ALZ-101
9.23.1 Drug Description
9.23.2 Outcomes

10. Phase I/II therapeutics Overview
10.1 Posiphen
10.1.1 Drug Description
10.1.2 Outcomes
10.1.3 Collaborators
10.2 PrimeProô/ PrimeMSKô
10.2.1 Drug Description
10.2.2 Outcomes
10.2.3 Collaborators
10.3 TB006
10.3.1 Drug Description
10.3.2 Outcomes
10.4 RO7126209
10.4.1 Drug Description
10.4.2 Outcomes
10.5 DNL593
10.5.1 Drug Description
10.5.2 Outcomes
10.5.3 Collaborators
10.6 BIIB080
10.6.1 Drug Description
10.6.1 Outcomes
10.7 E2814
10.7.1 Drug Description
10.7.2 Outcomes
10.8 Tdap
10.8.1 Drug Description
10.8.2 Outcomes
10.8.3 Collaborators
10.9 ACI-35.030/ JACI-35.054
10.9.1 Drug Description
10.9.2 Outcomes
10.9.3 Collaborators
10.10 ACI-24.060
10.10.1 Drug Description
10.10.2 Outcomes
10.10.3 Collaborators
10.11 IVL3003
10.10.1 Drug Description
10.10.2 Outcomes

11. Phase II therapeutics Overview
11.1 Lecanemab
11.1.1 Drug Description
11.1.2 Outcomes
11.1.3 Collaborators
11.2 Lomecel-B
11.2.1 Drug Description
11.2.2 Outcomes
11.2.3 Collaborators
11.3 AL002
11.3.1 Drug Description
11.3.2 Outcomes
11.3.3 Collaborators
11.4 AL001
11.4.1 Drug Description
11.4.2 Outcomes
11.5 CT1812 (Elaya)
11.5.1 Drug Description
11.5.2 Outcomes
11.6 APH-1105
11.6.1 Drug Description
11.6.2 Outcomes
11.7 ATH-1017
11.7.1 Drug Description
11.7.2 Outcomes
11.8 T-817MA
11.8.1 Drug Description
11.8.2 Outcomes
11.9 Montelukast buccal film
11.9.1 Drug Description
11.9.2 Outcomes
11.10 ABBV-916
11.10.1 Drug Description
11.10.2 Outcomes
11.11 Bepranemab
11.11.1 Drug Description
11.11.2 Outcomes
11.12 TB006
11.12.1 Drug Description
11.12.2 Outcomes
11.13 LY3372689
11.13.1 Drug Description
11.13.2 Outcomes
11.14 MW150
11.14.1 Drug Description
11.14.2 Outcomes
11.14.3 Collaborators
11.15 EX039
11.15.1 Drug Description
11.15.2 Outcomes
11.15.3 Collaborators
11.16 JNJ-42847922
11.16.1 Drug Description
11.16.2 Outcomes
11.17 REM0046127
11.17.1 Drug Description
11.17.2 Outcomes
11.18 Bryostatin 1
11.18.1 Drug Description
11.18.2 Outcomes
11.18.3 Collaborators
11.19 NanoLithiumÆ NP03
11.19.1 Drug Description
11.19.2 Outcomes
11.20 AstroStem
11.20.1 Drug Description
11.20.2 Outcomes
11.21 Gantenerumab
11.21.1 Drug Description
11.21.2 Outcomes
11.22 Semorinemab
11.22.1 Drug Description
11.22.1 Outcomes
11.23 Obicetrapib
11.23.1 Drug Description
11.23.2 Outcomes
11.24 ALZ-801
11.24.1 Drug Description
11.24.2 Outcomes
11.25 CY6463
11.25.1 Drug Description
11.25.2 Outcomes
11.26 Crenezumab
11.26.1 Drug Description
11.26.2 Outcomes
11.26.3 Collaborators
11.27 T3D-959
11.27.1 Drug Description
11.27.2 Outcomes
11.28 PMZ-1620
11.28.1 Drug Description
11.28.2 Outcomes
11.29 GV1001
11.29.1 Drug Description
11.29.2 Outcomes
11.30 ACZ885
11.30.1 Drug Description
11.30.2 Outcomes
11.31 PQ912
11.31.1 Drug Description
11.31.2 Outcomes
11.31.3 Collaborators
11.32 APH-1105
11.32.1 Drug Description
11.32.2 Outcomes
11.33 SLS-005
11.33.1 Drug Description
11.33.2 Outcomes
11.33.3 Collaborators
11.34 Flos gossypii flavonoids
11.34.1 Drug Description
11.34.2 Outcomes
11.34.3 Collaborators
11.35 Human Mesenchymal Stem cells (MSCs),
11.35.1 Drug Description
11.35.2 Outcomes
11.36 JNJ-63733657
11.36.1 Drug Description
11.36.2 Outcomes
11.37 IGC-AD1
11.37.1 Drug Description
11.37.2 Outcomes
11.38 TW001
11.38.1 Drug Description
11.38.2 Outcomes
11.39 ABvac40
11.39.1 Drug Description
11.39.2 Outcomes

12. Phase II/III therapeutics Overview
12.1 Tricaprilin
12.1.1 Drug Description
12.1.2 Outcomes
12.2 ANAVEX2-73
12.2.1 Drug Description
12.2.3 Outcomes
12.3 Piromelatine
12.3.1 Drug Description
12.3.2 Outcomes
12.3.3 Collaborators
12.4 AGB101
12.4.1 Drug Description
12.4.2 Outcomes
12.4.3 Collaborators

13. Phase III therapeutics Overview
13.1 Simufilam
13.1.1 Drug Description
13.1.2 Outcomes
13.1.3 Collaborators
13.2 ATH-1017
13.2.1 Drug Description
13.2.2 Outcomes
13.3 Lecanemab
13.3.1 Drug Description
13.3.2 Outcomes
13.3.3 Collaborators
13.4 Nilotinib BE
13.4.1 Drug Description
13.4.2 Outcomes
13.4.3 Collaborators
13.5 Brexpiprazole
13.5.1 Drug Description
13.5.2 Outcomes
13.5.3 Collaborators
13.6 Masitinib
13.6.1 Drug Description
13.6.2 Outcomes
13.7 Remternetug
13.7.1 Drug Description
13.7.2 Outcomes
13.8 Donanemab
13.8.1 Drug Description
13.8.2 Outcomes
13.9 NE3107
13.9.1 Drug Description
13.9.2 Outcomes
13.10 Gantenerumab
13.10.1 Drug Description
13.10.2 Outcomes
13.11 GV-971
13.11.1 Drug Description
13.11.2 Outcomes
13.12 Aducanumab
13.12.1 Drug Description
13.12.2 Outcomes
13.13 TRx0237
13.13.1 Drug Description
13.13.2 Outcomes
13.14 Semagludtide
13.14.1 Drug Description
13.14.2 Outcomes
13.15 BPDO-1603
13.15.1 Drug Description
13.15.2 Outcomes
13.16 AR1001
13.16.1 Drug Description
13.16.2 Outcomes
13.17 KarXT
13.17.1 Drug Description
13.17.2 Outcomes
13.18 AXS-05
13.18.1 Drug Description
13.18.2 Outcomes

14. Phase IV therapeutics Overview
14.1 Choline Alfoscerate
14.1.1 Drug Description
14.1.2 Outcomes
14.2 Ebicomb
14.2.1 Drug Description
14.2.2 Outcomes
14.3 Rivastigmine
14.3.1 Drug Description
14.3.2 Outcomes
14.4 GV-971
14.4.1 Drug Description
14.4.2 Outcomes

15. Preclinical Phase therapeutics Overview
15.1 PMN310
15.1.1 Drug Description
15.1.2 Outcomes
15.1.3 Collaborators
15.2 PRX123
15.2.1 Drug Description
15.2.2 Outcomes

16. Pipeline analysis, By molecule type
16.1 Alzheimer's Therapeutics Comparative Review, by Molecule type

17. Pipeline Analysis, By Route of Administration
17.1 Alzheimer's Therapeutics Comparative Review, By Route of Administration
Healthcare and Pharmaceuticals

Asia Pacific Nuclear Medicine Market Size, Share, Trends & Analysis by Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), by Application (Neurology, Cardiology, Oncology, Others), by End User (Hospitals & Clinics, Diagnostic Centers, Others) and Region, with Forecasts from 2024 to 2034.

  Price : US$ 3450   Date : Oct 2024
  Category : Healthcare and Pharmaceuticals   Pages : 191
Healthcare and Pharmaceuticals

Europe Nuclear Medicine Market Size, Share, Trends & Analysis by Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), by Application (Neurology, Cardiology, Oncology, Others), by End User (Hospitals & Clinics, Diagnostic Centers, Others) and Region, with Forecasts from 2024 to 2034.

  Price : US$ 3450   Date : Oct 2024
  Category : Healthcare and Pharmaceuticals   Pages : 196
Healthcare and Pharmaceuticals

North America Nuclear Medicine Market Size, Share, Trends & Analysis by Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), by Application (Neurology, Cardiology, Oncology, Others), by End User (Hospitals & Clinics, Diagnostic Centers, Others) and Region, with Forecasts from 2024 to 2034.

  Price : US$ 3450   Date : Oct 2024
  Category : Healthcare and Pharmaceuticals   Pages : 194
Healthcare and Pharmaceuticals

Global Nuclear Medicine Market Size, Share, Trends & Analysis by Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), by Application (Neurology, Cardiology, Oncology, Others), by End User (Hospitals & Clinics, Diagnostic Centers, Others) and Region, with Forecasts from 2024 to 2034.

  Price : US$ 3750   Date : Oct 2024
  Category : Healthcare and Pharmaceuticals   Pages : 205
Healthcare and Pharmaceuticals

Chronic Kidney Disease Management Technology Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)

  Price : US$ 3500   Date : Oct 2024
  Category : Healthcare and Pharmaceuticals   Pages : 167

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.

Related Reports

Asia Pacific Nuclear Medicine Market Size, Share, Trends & Analysis By Product (Diagnostics (SP...
View More
Europe Nuclear Medicine Market Size, Share, Trends & Analysis By Product (Diagnostics (SPECT, P...
View More
North America Nuclear Medicine Market Size, Share, Trends & Analysis By Product (Diagnostics (S...
View More
Global Nuclear Medicine Market Size, Share, Trends & Analysis By Product (Diagnostics (SPECT, P...
View More
Chronic Kidney Disease Management Technology Market Size And Share Analysis - Growth Trends And...
View More

Trusted Clients
A-T- Kearney.png
AbbVie.png
Agrinos.png
AIF-Metrics.png
Akzo-Nobel.jpg
Alfi-GMBH.png
Allergan.png
Almasra-Scientific-Bureau.jpg
ALPMA.jpg
Americana-Foods.png
ANP.png
Aptar-Group-Germany.jpg
asahi-kasei.png
ATC.png
atlas-servair.jpg
ATOS.png
Avalon.png
biofishency.png
biomx.png
borealisgroup.png
Cape-Peninsula.png
CBRE.png
Cennerv-Pharma.jpg
Clearponds.png
Compass-Group.png
Cortag-Industria.png
Covis-Pharma.jpg
DAIMLER-AG.jpg
Edipresse-Media.jpg
Epson.png
Evonik-Industries-AG.png
ExcelSource.png
Fingo.png
Firstkind.png
FLM-Foodingredients.png
Freudenberg.png
Fueltrax.jpg
Fugro-International.png
Fuji-Films.png
Funky-Sound-Studio.png
GALTWAY.png
Gartner.png
GBSC.png
Global-Information.jpg
Hanwha-Total-Petrochemical.png
Hebrew.png
Horiba-Mira.png
Hunter-and-Co-Investments.png
Hyosung.png
Hyssopus-Organics.jpg
IBSA.png
Ideagen.png
IMS.png
InSinkErator.png
Intas-Pharma.png
IntelMed-Sarl.png
Interdiligence-Consulting.png
Israel-Shopyards.png
Johnsons-Controls.png
kakaxi.jpg
KORDSA.png
kotra.png
KPMG.png
lantmannen.png
LEK.png
LG.jpg
Makuri-Technology.jpg
Mallinckrodt.png
Mappo.png
Maprimed.jpg
mcns.jpg
MED-EL.png
Mehr-Azin-Pouya-Sahand.png
Molkerei-Ammerland-eG.png
Monty-Holding.jpg
mpmaterials.png
Mundipharma.png
Nasco.png
Nitto.png
Nouryon.png
NOXTAK.png
Oskars.png
Paidotribo.png
Parnell-Pharmaceuticals.png
Podravka.png
ppg.png
Privi.png
Publicis Groupe.png
Qvetech.jpg
R3P.jpg
Samsung.png
Sapient.png
SEW-EURODRIVE.png
Shivananda.jpg
Silver-Clouds.png
SMIT.jpg
SOLVIAS.png
Spectrum.png
SR-Instruments-Oy.png
Star-Seed.png
Stryker -ENT.png
Synjenta.png
Terumo-Corp.png
TherOzone.png
Toshiba.png
TT-Electronics.png
umbc.edu.png
Vard.jpg
Vital-Xense.png
Walraven.png
Wlgore.png
Woodmac.png
WWF-UK.png
ZENOAQ.png
Zuellig-Pharma.png
Contact us

sales@worldwidemarketreports.com

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

phoneiconU.S. : +1 415 871 0703

phoneiconU.K. : +44-203-289-4040

phoneiconAUS. :+61-2-4786-0457

phoneiconIndia :+91-848-285-0837

Menu
Quick Links
Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved